Use of Drug-Eluting Stents in Acute Myocardial Infarction. A Systematic Review and Meta-Analysis

Journal of the American College of Cardiology

Volumn 53, Issue 18, 2009, Pages 1677-1689

  Brar, Somjot S ^a   Leon, Martin B ^a   Stone, Gregg W ^a   Mehran, Roxana ^a   Moses, Jeffrey W ^a   Brar, Simerjeet K ^a   Dangas, George ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

drug eluting; meta analysis; meta regression; myocardial infarction; stent; systematic review

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; TIROFIBAN;

ACUTE HEART INFARCTION; ARTICLE; BARE METAL STENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; SENSITIVITY ANALYSIS; ST SEGMENT ELEVATION; STENT THROMBOSIS; SYSTEMATIC REVIEW;

CONFIDENCE INTERVALS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; REGISTRIES; REGRESSION ANALYSIS; RISK;

EID: 65249147145     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.03.013     Document Type: Article

References (66)

1. Sigwart U., Puel J., Mirkovitch V., Joffre F., and Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316 (1987) 701-706
2. Fischman D.L., Leon M.B., Baim D.S., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331 (1994) 496-501
3. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
4. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
5. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
6. Shuchman M. Trading restenosis for thrombosis?. New questions about drug-eluting stents. N Engl J Med 355 (2006) 1949-1952
7. Sianos G., Papafaklis M.I., Daemen J., et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol 50 (2007) 573-583
8. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
9. De Luca G., Stone G.W., Suryapranata H., et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Int J Cardiol 133 (2008) 213-222
10. Kastrati A., Dibra A., Spaulding C., et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 28 (2007) 2706-2713
11. Pasceri V., Patti G., Speciale G., Pristipino C., Richichi G., and Di Sciascio G. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J 153 (2007) 749-754
12. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
13. Van Houwelingen H.C., Zwinderman K.H., and Stijnen T. A bivariate approach to meta-analysis. Stat Med 12 (1993) 2273-2284
14. Bland J.M., and Altman D.G. Regression towards the mean. BMJ 308 (1994) 1499
15. Sharp S.J., Thompson S.G., and Altman D.G. The relation between treatment benefit and underlying risk in meta-analysis. BMJ 313 (1996) 735-738
16. Begg C.B., and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994) 1088-1101
17. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
18. Duval S., and Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000) 455-463
19. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 (1999) 1896-1900
20. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000) 2008-2012
21. Di Lorenzo E., Varricchio A., Lanzillo T., et al. Paclitaxel and sirolimus implantation in patients with acute myocardial infarction (abstr). Circulation 112 (2005) U538
22. Helsinki Area Acute Myocardial Infarction Treatment Re-Evaluation-Should the Patients Get a Drug-Eluting or Normal Stent (HAAMU-STENT). http://www.cardiosource.com/clinicaltrials/trial.asp?trialID = 1492 Accessed May 30, 2008
23. Spaulding C., Henry P., Teiger E., et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
24. Laarman G.J., Suttorp M.J., Dirksen M.T., et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 (2006) 1105-1113
25. Menichelli M., Parma A., Pucci E., et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 49 (2007) 1924-1930
26. Chechi T., Vittori G., Biondi Zoccai G.G., et al. Single-Center Randomized Evaluation of Paclitaxel-Eluting Versus Conventional Stent in Acute Myocardial Infarction (SELECTION). J Interv Cardiol 20 (2007) 282-291
27. Valgimigli M., Percoco G., Malagutti P., et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293 (2005) 2109-2117
28. Valgimigli M., Campo G., Percoco G., et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 299 (2008) 1788-1799
29. Kelbaek H., Thuesen L., Helqvist S., et al. Drug-eluting versus bare metal stents in patients with ST-segment elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 118 (2008) 1155-1162
30. A Prospective Randomized Controlled Trial to Evaluate the Efficacy of Drug-Eluting Stents Versus Bare-Metal Stents for the Treatment of Acute Myocardial Infarction (MISSION) Trial. http://www.cardiosource.com/clinicaltrials/trial.asp?trialID=1517 Accessed May 30, 2008
31. Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI Stent). http://www.cardiosource.com/clinicaltrials/trial.asp?trialID=1754 Accessed October 15, 2008
32. Pittl U., Kaiser C., Brunner-La Rocca H.P., et al. Safety and efficacy of drug eluting stents versus bare metal stents in the primary angioplasty of patients with acute ST-elevation myocardial infarction: a prospective randomized study. Eur Heart J 27 (2006) 650
33. Diaz de la Llera L.S., Ballesteros S., Nevado J., et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J 154 (2007) 164
34. Kukreja N., Onuma Y., Garcia-Garcia H., Daemen J., van Domburg R., and Serruys P.W. Primary percutaneous coronary intervention for acute myocardial infarction: long-term outcome after bare metal and drug-eluting stent implantation. Circ Cardiovasc Intervent 1 (2008) 103-110
35. Vagaonescu T.D., Moreyra A.E., Wilson A.C., Cosgrove N.M., and Kostis J.B. Long-term mortality in ST-T segment and non ST-T segment myocardial infarction after drug-eluting stents and bare metal stents implantation in New Jersey: the MIDAS registry. Presented at: Transcatheter Cardiovascular Therapeutics, Washington, DC: October 20-25, (2007)
36. Bose R., Gupta G., Grayburn P.A., Laible E.A., Kang M.J., and Choi J.W. Safety of drug-eluting stents in the coronary artery in ST-elevation myocardial infarction at a single high-volume medical center. Am J Cardiol 100 (2007) 949-952
37. Cheneau E., Rha S., Kuchulakanti P., et al. Impact of sirolimus-eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty. Cathet Cardiovasc Intervent 65 (2005) 469-472
38. Kupferwasser L.I., Amorn A., Kapoor N., et al. Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction. Cathet Cardiovasc Intervent 70 (2007) 1-8
39. Mauri L., Silbaugh T.S., Garg P., et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 359 (2008) 1330-1342
40. Newell M.C., Henry C.R., Sigakis C.J., et al. Comparison of safety and efficacy of sirolimus-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction. Am J Cardiol 97 (2006) 1299-1302
41. Percoco G., Manari A., Guastaroba P., et al. Safety and long-term efficacy of sirolimus eluting stent in ST-elevation acute myocardial infarction: the REAL (Registro REgionale AngiopLastiche Emilia-Romagna) registry. Cardiovasc Drugs Therapy 20 (2006) 63-68
42. Romano M., Buffoli F., Tomasi L., Corrado L., Ferrari M., and Zanini R. Safety and effectiveness of drug eluting stent in patients with ST elevation myocardial infarction undergoing primary angioplasty. Cathet Cardiovasc Intervent 71 (2008) 759-763
43. Slottow T.L., Steinberg D.H., Roy P., et al. Drug-eluting stents are associated with similar cardiovascular outcomes when compared with bare metal stents in the setting of acute myocardial infarction. Cardiovasc Revasc Med 9 (2008) 24-28
44. Vlaar P., Rihal C., Singh M., et al. Safety and efficacy of drug-eluting stent for ST-segment elevation myocardial infarction in an unselected consecutive cohort. Cathet Cardiovasc Intervent 71 (2008) 764-769
45. Hannan E., Racz M., Walford G., et al. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol Intv 1 (2008) 129-135
46. Shishehbor M., Amini R., Oliveria L., et al. Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction. J Am Coll Cardiol Intv 1 (2008) 227-232
47. Jensen L.O., Maeng M., Thayssen P., et al. Two-year clinical outcome following primary precutaneous coronary intervention with drug-eluting and bare metal stent in patients with ST-segment elevation myocardial infarction. Presented at: Transcatheter Cardiovascular Therapeutics, Washington, DC: October 12-17, (2008)
48. Brodie B.R., Stuckey T., Downey W., et al. Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group. Cathet Cardiovasc Interv 72 (2008) 893-900
49. Lemos P.A., Saia F., Hofma S.H., et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared with conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 43 (2004) 704-708
50. Nakamura S., Bae J., Cahyadi Y.H., Udayachalerm W., Tresukosol D., and Tansuphaswadikul S. Three-year follow-up of patients with ST-segment evelation acute myocardial infarction treated with sirolimus-eluting stent and paclitaxel-eluting stent: multicenter registry in Asia (abstr). Am J Cardiol 98 (2006) 76M
51. Steg P.G. Increased all-cause mortality at 2 year follow-up after PCI with drug-eluting stents vs bare metal stents in acute coronary syndromes: the GRACE registry experience. Presented at: European Society of Cardiology, September 4, (2007) Vienna, Austria
52. Garg P., Normand S.L., Silbaugh T.S., et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation 118 (2008) 2277-2285
53. Azzarelli S., Amico F., Galassi A.R., Giacoppo M., Argentino V., and Fiscella A. Two-year clinical follow up of coronary drug-eluting stent in patients at high risk for coronary restenosis. J Invas Cardiol 20 (2008) 62-66
54. Sabate M., Jimenez-Quevedo P., Angiolillo D.J., et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the Diabetes and Sirolimus-Eluting Stent (DIABETES) trial. Circulation 112 (2005) 2175-2183
55. Kirtane A.J., Ellis S.G., Dawkins K.D., et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol 51 (2008) 708-715
56. Chechi T., Vecchio S., Vittori G., et al. ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. J Am Coll Cardiol 51 (2008) 2396-2402
57. de la Torre-Hernandez J.M., Alfonso F., Hernandez F., et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 51 (2008) 986-990
58. Brar S.S., Kim J., Brar S.K., et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol 51 (2008) 2220-2227
59. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
60. Moreno R., Fernandez C., Hernandez R., et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45 (2005) 954-959
61. Nakazawa G., Finn A.V., Joner M., et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 118 (2008) 1138-1145
62. Wenaweser P., Daemen J., Zwahlen M., et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 52 (2008) 1134-1140
63. King III S.B., Smith Jr. S.C., Hirshfeld Jr. J.W., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51 (2008) 172-209
64. Mehran R., Brodie B., Cox D.A., et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial: study design and rationale. Am Heart J 156 (2008) 44-56
65. Thompson S.G., Smith T.C., and Sharp S.J. Investigating underlying risk as a source of heterogeneity in meta-analysis. Stat Med 16 (1997) 2741-2758
66. McIntosh M.W. The population risk as an explanatory variable in research synthesis of clinical trials. Stat Med 15 (1996) 1713-1728